# The project is being implemented under an Indo-Singapore collaborative framework in partnership with Biocell Innovations.

*biotech · news · 2026-05-14 · The Tribune*

## Key points

- The Technology Development Board partnered with Helix Cell Therapeutics to develop dual-targeting CAR-T therapy for Multiple Myeloma.
- The new CAR-T therapy will simultaneously target BCMA and CD19 markers on Multiple Myeloma cells.
- This project operates under an Indo-Singapore collaborative framework with Biocell Innovations as a partner.
- The initiative includes conducting a Phase I clinical trial for patients who have exhausted current treatment options.
- This project aims to accelerate indigenous innovation in advanced immunotherapy and strengthen India's biotech capabilities.

**Companies:** Helix Cell Therapeutics Private Limited, Biocell Innovations
**Countries:** India, Singapore

[Read the full story on The Tribune](https://www.tribuneindia.com/news/business/govt-signs-agreement-to-develop-new-car-t-therapy-for-multiple-myeloma/)

---

Canonical: https://newsio.io/n/e84c6fe9-c8f2-4b65-86d7-3ce29efc82f3/the-project-is-being-implemented-under-an-indo-singapore-collaborative-framework
Summarized by Newsio from The Tribune. https://newsio.io/how-it-works